BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 31, 2009
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 8/28 cls
Alkermes Inc. (NASDAQ:ALKS) Jefferies David Windley Downgrade Hold (from buy) -10% $9.37
Windley also lowered his price target to $11.50 from $14 after Johnson & Johnson (NYSE:JNJ) discontinued development of a 4-week formulation of risperidone following a portfolio review. The long-acting injectable formulation of risperidone is delivered using Medisorb technology from Alkermes and was in Phase I testing for schizophrenia (see B14).
Incyte Corp. (NASDAQ:INCY) UBS Jeff Elliott Price target Buy 4% $6.76

Read the full 659 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >